Dr. Xiangmin Cui is the Founder and serves as Managing Director at Decheng Capital. He also serves as Board Member at ShapeTX, Cue Health and Ariagen. He also served as Board Member at Hummingbird Bioscience. He served as a Board Member at VelosBio. Prior to founding Decheng Capital in 2011, Dr. Cui was an Investment Partner at Bay City Capital, a leading international life science venture capital firm, and focused on evaluating investment opportunities as well as its initiatives in China. Dr. Cui was previously Director of Strategic Investment for the Southern Research Institute, an organization that discovered and developed six anti-cancer drugs approved by the US Food and Drug Administration. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals. He served as Board Member at GenapSys. He served as the Chief Scientific Officer and Executive Vice President of Pan Pacific Pharmaceuticals from 1998 to 2002 and Chief Executive Officer and President of Huron Biopharmaceuticals from 2003 to 2005, respectively. In these positions, he led efforts in the discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui is a member of the board of directors of GeneWeave Biosciences, Ketai Medical, Shenzhen GeneMDx Biotechnology, Accuragen, and Sinomed. His investment portfolio also includes Ion Torrent Systems (acquired by Life Technologies for $725M), GenturaDx (acquired by Luminex), China Biologic Products (NASDAQ: CBPO), Epizyme (NASDAQ: EPZM), and Sunesis (NASDAQ: SNSS). Dr. Cui was also a co-founder of network, a San Francisco-based non-profit organization dedicated to serving Chinese communities in North America. He received his Ph.D. in Cancer Biology from Stanford University and his BS in Molecular Biology from Peking University. He also serves as the Board Member at EpimAb Biotherapeutics. He serves as Board Member at Alpine Immune Sciences.